The "Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin" report has been added to ResearchAndMarkets.com' s offering. -New York esophageal squamous cell carcinoma-1: NY-ESO-1. The original reports were published in May and June 2018, respectively:.
The "Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin" report has been added to ResearchAndMarkets.com' s offering. Melanoma-associated antigen A: MAGE-A New York esophageal squamous cell carcinoma-1: NY-ESO-1 Human telomerase reverse transcriptase: hTERT Wilms tumor 1: WT1 Preferentially expressed antig
ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other EventsItem 8.01 Other Events. On June 15, 2018, Acceleron Pharma Inc. issued a press release titled "Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association." A copy of the press release is a
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the closing of an underwritten public offering of units for gross proceeds of $13.8 million, which includes the full exercise of the underwriter`s over-allotment option to.
"Active Pharmaceutical Ingredients Market" The report titled Global Active Pharmaceutical Ingredients Market 2018 Research Report implements an exhaustive study on Market Research Future. This Report Cover market size, growth rate, opportunities, market Dynamics and Factor Analysis. And also cover the other information such as Active Pharmaceutical
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today an expansion of its relationship with Corium International, Inc. to include the Company s long-acting transdermal patch, AQS1303, for the treatment of nausea and vomiting in pregnancy.
DURHAM- Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of William Coppola as Intellectual Property Counsel, reporting to John
Agios Pharmaceuticals, Inc. AGIO, announced the initiation of the phase III ACTIVATE study which will evaluateits lead rare genetic diseases candidate, AG-348 in patients with Pyruvate kinase deficiency who do not receive regular blood transfusions. The ACTIVATE study will enroll about 80 adult patients with PK deficiency who do not receive regular
CAMBRIDGE- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the initiation of the Phase 3 ACTIVATE trial evaluating AG-348, a first-in-class, selective, small molecule activator of the pyruvate kinase-R enzyme. ACTIVATE is a randomized, placebo-controlled trial that
AIVITA Biomedical, a biotech company specializing in innovative stem cell applications, announced today the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a Phase II clinical trial investigating the Company`s ROOT OF CANCER technology in patients with glioblastoma multiforme. This will be the third...
BOSTON- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Jason G. Duncan as General Counsel and Secretary. In this role, Mr. Duncan will be responsible for Albireo's global legal affairs, and serve as a strategic advisor to the executive team and
Alexion Pharmaceuticals said that it has submitted a biologics license application to the US Food and Drug Administration, seeking approval for its C5 complement inhibitor ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Alexion executive vice president and research& development head John Orloff said: This first...
Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced Mary T. Szela has joined its Board of Directors. Ms. Szela brings extensive medical management and leadership experience to Alimera's Board. Prior to joining Surefire Medical as its CEO and President, Ms. Szela ser
Alligator Bioscience, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, will present additional preclinical data for the drug candidate ATOR-1017 at the 3rd Annual World Preclinical Congress in Boston, US. ATOR-1017 is a monoclonal antibody being developed for the treatment of metastasizing...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it plans to host its 5 th annual series of RNAi Roundtable webcasts this summer. The 2018 series will offer a range of presentations from Alnylam scientists, clinical collaborators, and patients or patient advocates, who will review recent progress in m
Amgens Blincyto has been granted a full European licence in a form of blood cancer following data showing the drug almost doubled overall survival time compared with standard therapy. The company said the European Commission granted the marketing authorisation based on overall survival data from the phase 3 TOWER study, in adults with Philadelphia.
Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advancing a novel cancer immunotherapy, today announced it received clearance from the Food and Drug Administration to initiate the first Phase 1 clinical trial of its immuno-oncology drug candidate AMXT 1501, a small molecule polyamine uptake inhibitor, and the approve
Houston, TX 06/21/2018 Research N Reports has announced the addition of a new market intelligence report. Targeted pharmaceuticals for the global market have reached$ 89 billion in 2017. The global anticancer market is showing significant growth and is expected to grow at a significant CAGR over the period from 2018 to 2021. Some of the key p
VANCOUVER- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that it will present at the first annual Roivant Pipeline Day on July 10, 2018, at 4:00 p.m. ET. Roivant Pipeline Day will be held on Tuesday, July 10, 2018, in New York City. Arbutus Biopharma Corporation is a publicly tra
SAN DIEGO- Arcturus Therapeutics Ltd., a leading RNA medicines company, today announced that it plans to present at the JMP Securities Life Sciences Conference on Thursday, June 21, in New York City. Founded in 2013 and based in San Diego, Arcturus Therapeutics Ltd. is an RNA medicines company with enabling technologies- UNA Oligomer chemistry and
BOULDER- Array BioPharma Inc. announced that it will present updated safety and efficacy results, including overall survival data, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF-mutan
-Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has completed dosing and clinical visits in its Phase 1 study of its proprietary topical Endoxifen in men. We are now proceeding to the final stages of this stu
AVROBIO, Inc., a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose, today announced the pricing of its initial public offering of 5,247,958 shares of common stock at a public offering price of $19.00 per share, before underw
BRIDGEWATER- Bausch+ Lomb, a leading global eye health company, today announced that it has received Pre-Market Approval from the U.S. Food and Drug Administration for the enVista toric MX60T, the company's first hydrophobic acrylic intraocular lens for astigmatism correction. 'Building on the proven features and benefits of the enVista family of I